Concepedia

Publication | Open Access

Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma

DOIFull Paper Access

238

Citations

24

References

2010

Year

John M. Kirkwood, Paul Lorigan, Peter Hersey, Axel Hauschild, Caroline Robert, David F. McDermott, Margaret Marshall, Jesús Gómez-Navarro, Jane Liang, C. A. Bulanhagui
Clinical Cancer Research

Abstract

Tremelimumab showed an objective response rate of 6.6%, with all responses being durable > or =170 days since enrollment, suggesting a potential role for tremelimumab in melanoma.

References

YearCitations

Page 1